SEARCH

SEARCH BY CITATION

FilenameFormatSizeDescription
hiv12047-sup-0001-si.TIF66K

Fig. S1 Individual minimum plasma concentrations of total darunavir (A), unbound darunavir (B) and total ritonavir (C) after administration of darunavir/ritonavir 600/100 mg twice daily (bid), during the second and third trimesters and postpartum.

hiv12047-sup-0002-si.pdf73K

Fig. S2 Mean (standard error) plasma concentration–time curves for albumin (A) and α1-acid glycoprotein (AAG) (B) assessed at various time-points throughout the study.

hiv12047-sup-0003-si.pdf74K

Fig. S3 Antiviral activity expressed as percentage response rate (A) (only patients who completed the study in its entirety are included) and status of the immune system expressed as median percentage CD4 count (B) assessed at various time-points throughout the study.

hiv12047-sup-0004-si.doc65K

Table S1 Baseline demographics, disease characteristics and study discontinuations.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.